Microglial/macrophage activation in the cerebrospinal fluid of neuromyelitis optica spectrum disorders
Open Access
- 28 October 2022
- journal article
- research article
- Published by Wiley in Brain and Behavior
- Vol. 12 (12) , e2798
Abstract
Aim: The aims of this pilot study were to investigate the levels of biomarkers of microglial/macrophage activation—YKL‐40, sCD163, and sCD14—in patients with neuromyelitis optica spectrum disorder (NMOSD) and determine the possible associations between these biomarkers and Expanded Disability Status Scale (EDSS) scores.Methods: We measured the levels of three microglia‐/macrophage‐related proteins (YKL‐40, soluble CD163, and soluble CD14) in cerebrospinal fluid (CSF) using enzyme‐linked immunosorbent assays. In addition, patients’ neurological disability levels were assessed using EDSS scores.Results: NMOSD patients had significantly higher CSF levels of YKL‐40(210.52 ± 161.62 for NMOSD and 63.18 ± 9.22 for control), sCD163 (87.23 ± 56.85 for NMOSD and 58.14 ± 7.66 for control), and sCD14 (68.22 ± 24.11 for NMOSD and 55.75 ± 9.48 for control) compared with controls. Furthermore, these biomarker levels were positively correlated with EDSS scores in patients with NMOSD (r = 0.303, p = .002 for YKL‐40; r = 0310, p = .001 for sCD14; r = 0.250, p = .011 for sCD163), but not in patients with multiple sclerosis or glial fibrillary acidic protein astrocytopathy.Conclusion: Our findings suggest that microglial/macrophage activation may be implicated in the pathogenesis of NMOSD.Keywords
Funding Information
- National Natural Science Foundation of China (81673950; 81901239)
This publication has 32 references indexed in Scilit:
- Innate immunity in the central nervous systemJournal of Clinical Investigation, 2012
- Soluble CD163: a biomarker linking macrophages and insulin resistanceDiabetologia, 2012
- Pathology of Demyelinating DiseasesAnnual Review of Pathology: Mechanisms of Disease, 2012
- Soluble CD163Scandinavian Journal of Clinical and Laboratory Investigation, 2011
- Chitinase effects on immune cell response in neuromyelitis optica and multiple sclerosisMultiple Sclerosis Journal, 2010
- YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's DiseaseBiological Psychiatry, 2010
- Review: Soluble innate immune pattern-recognition proteins for clearing dying cells and cellular components: implications on exacerbating or resolving inflammationInnate Immunity, 2010
- In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseasesJournal of Neuroinflammation, 2010
- Increased serum levels of soluble CD14 indicate stable multiple sclerosisJournal of Neuroimmunology, 2006
- Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitmentBrain, 2005